Targets › DCK
5 programs from 5 companies in 5 trials: 3 Phase 2, 2 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.
Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine. Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. (UniProt, P27707)
Open in Phaseline: the race on DCK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peking Union Medical College Hospital | GC Combination of gemcitabine and cisplatin | RRM1, RRM2, DCK, ERCC1 | Phase 2 | Biliary Tract Neoplasms Immunotherapy | Jan 2027 |
| Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Pracytarabine Pyrimidine nucleoside analog | DCK | Phase 2 | HCC | Feb 2027 |
| CellSight Technologies | [18F]F-AraG Radiolabeled substrate for deoxyguanosine kinase (dGK) and deoxycytidine kinase (dCK), bot | DGK, DCK | Phase 2 | Covid19 | Oct 2027 |
| Trethera | TRE-515 Deoxycytidine kinase (dCK) inhibitor | DCK | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| Jiangsu Hansoh Pharmaceutical | HS-10566 Intravesical gemcitabine delivery system | RRM1, RRM2, DCK | Phase 1 | High-risk Non-muscle-invasive Bladder Cancer | Apr 2028 |
Solid Tumor, Adult (1) Covid19 (1) HCC (1) High-risk Non-muscle-invasive Bladder Cancer (1) Biliary Tract Neoplasms Immunotherapy (1)
small molecule (5)
Trethera (1) CellSight Technologies (1) Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1) Jiangsu Hansoh Pharmaceutical (1) Peking Union Medical College Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.